Fri, Mar 6, 2015, 1:24 PM EST - U.S. Markets close in 2 hrs 36 mins


% | $
Quotes you view appear here for quick access.

Momenta Pharmaceuticals Inc. Message Board

perryfinker 2 posts  |  Last Activity: Jan 24, 2015 4:05 PM Member since: Jul 14, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    For those with ramp up panic syndrome

    by oshinator54 Jan 24, 2015 3:07 PM
    perryfinker perryfinker Jan 24, 2015 4:05 PM Flag

    Also, everyone keeps leaving out the party that ESRX v-pak Rxs are not being reported per a contractual obligation. So the real Rx # so far is 180 + that ESRX #.

  • Reply to

    Script numbers

    by ruby2626 Jan 9, 2015 1:31 PM
    perryfinker perryfinker Jan 10, 2015 11:35 AM Flag

    IMS is underreprting V-Pak Rx data:

    Those watching the launch through weekly prescription data from IMS Health (NYSE:IMS) were stymied by IMS' announcement that some of the prescriptions were not being reported due to "a contractual condition between a supplier and the manufacturer," and thus are being underreported, according to RBC Capital Markets analyst Michael Yee. Yee noted that sales of Viekira's competitors, Gilead Sciences' (NASDAQ:GILD) Harvoni and Sovaldi, were continuing in line with expectations for the two weeks after the Viekira launch, and were on track to do at least $12 billion this year.

14.47-0.20(-1.36%)1:24 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.